For generations, cystic fibrosis has been a disease measured in losses — of breath, of years, of possibility. Now, researchers at Charité hospital in Berlin have found that a triple-drug therapy, already transformative for older patients, restores nearly complete molecular function in children ages 2 to 11 — a degree of repair twice as powerful as what is seen in adolescents and adults. The finding, published in September 2026, raises a quiet but urgent question that medicine is only beginning to answer: how much suffering might be prevented if treatment begins before the body has had time to
Triple therapy restores near-normal lung function in young CF patients
Cystic fibrosis patients experience thick mucus in lungs, frequent respiratory infections, and pancreatic, liver, and intestinal complications; early triple therapy treatment may prevent irreversible tissue damage.
Nearly indistinguishable from children without cystic fibrosis
Mark
So triple therapy has been around since 2020, but this study is the first time anyone measured how well it actually restores the broken channels in young children?
Mimi
Not quite the first time anyone measured it—they'd done sweat tests before, which showed children were responding better. But this is the first direct functional measurement of the CFTR channels themselves in children that age. They actually cultured tissue samples and measured the electrical current flowing through the channels.
Luke
And that's a meaningful difference? Sweat tests are already a clinical standard.
Mimi
It is, because it shows the mechanism. The sweat test tells you the salt concentration is lower, which suggests the channels are working better. But measuring the actual ion transport tells you how much better—and in this case, it was 90 to 100 percent restoration in children, versus about 50 percent in adults.
Mark
Why would children respond so much better than adults?
Mimi
That's the question they're still trying to answer. But the correlation with age is clear: younger children had more complete restoration than older children, who had more than adolescents and adults.
Luke
Do we know if this actually prevents the lung damage long-term? The study was only four months.
Mimi
No, that's still unknown. The hope is that early treatment prevents irreversible scarring and tissue changes, but they haven't followed these children long enough to prove it yet.
Mark
So what happens next?
Mimi
They want to study even younger children—potentially under age 2—if the drug gets approved for that age group. And they're planning molecular-level studies to understand why the effect is so much stronger in young kids.
Luke
And the practical question: how many children actually have access to this drug? It's been approved, but is it being prescribed widely?
Mimi
The source doesn't address that. We know it's approved for children 2 and older, but uptake and access aren't discussed here.
The Pulse
- Children ages 2–11 receiving triple therapy saw CFTR channel function restored to 90–100%, compared to just 50% in older patients — a gap so large it surprised even the researchers who found it.
- Cystic fibrosis causes thick mucus to accumulate in the lungs, inviting chronic infection and slowly scarring tissue in ways that, once set, cannot be undone.
- The Charité team measured electrical current through intestinal tissue samples before and after four months of treatment, giving them a precise, cellular-level picture of how well the therapy was working in young bodies.
- A clear age gradient emerged: the younger the child, the more complete the restoration — suggesting that the biology of early childhood may amplify the drug's ability to correct the underlying defect.
- Researchers are now preparing to study children younger than 2 and to use single-cell analysis to understand why young tissue responds so differently, with the hope of expanding treatment eligibility further.
For generations, cystic fibrosis has been a disease measured in losses — of breath, of years, of possibility. Now, researchers at Charité hospital in Berlin have found that a triple-drug therapy, already transformative for older patients, restores nearly complete molecular function in children ages 2 to 11 — a degree of repair twice as powerful as what is seen in adolescents and adults. The finding, published in September 2026, raises a quiet but urgent question that medicine is only beginning to answer: how much suffering might be prevented if treatment begins before the body has had time to forget what health feels like.
Cystic fibrosis is caused by a genetic defect that disables CFTR proteins — molecular channels in mucous membranes that regulate salt and water balance. When they fail, lungs fill with thick mucus, infections take hold, and the pancreas, liver, and intestines all suffer. For most of the disease's history, treatment could only manage these consequences, not address their source.
That changed with the arrival of triple therapy — elexacaftor, tezacaftor, and ivacaftor — a combination designed to correct the underlying genetic malfunction. Approved for children as young as 6 in 2022 and extended to age 2 in 2023, the treatment had already shown strong results. But clinicians noticed that younger patients seemed to respond with unusual force, and a team at Charité – Universitätsmedizin Berlin decided to measure exactly how much.
Dr. Simon Gräber and colleagues enrolled 26 children between ages 2 and 11, all carrying the F508del mutation. Before and after four months of treatment, they assessed lung function, ran sweat tests, and cultured small intestinal tissue samples to measure electrical current through CFTR channels — a direct indicator of how well the proteins were functioning.
The results astonished them. Where triple therapy restores channel function to roughly 50% in adolescents and adults, it brought young children to 90–100% — nearly indistinguishable from children without the disease. The pattern held across ages: a 3-year-old responded more completely than a 10-year-old, who responded more completely than a teenager. 'Such positive findings regarding the functional efficacy of triple therapy in children are truly remarkable and offer hope,' said Prof. Marcus Mall, who led the department.
The mechanism behind this age gradient is not yet understood, but its implications are clear. Lung damage and tissue scarring accumulate over years and cannot be reversed. If treatment can begin early enough — possibly even before age 2 — it may hold ground that would otherwise be lost. The Charité team plans to study younger children and to use single-cell analysis to understand how the therapy works at the molecular level, pursuing a future in which cystic fibrosis is intercepted before it has the chance to leave its mark.
Cystic fibrosis has long been a disease that steals time. The genetic defect that causes it breaks a fundamental mechanism in the body—molecular channels called CFTR proteins that sit in mucous membranes and regulate the balance of water and salt. Without them working properly, the lungs fill with thick, sticky mucus. Infections follow. The pancreas, liver, and intestines suffer. Until recently, life expectancy for children born with the condition was sharply curtailed.
Then, in 2020, a new treatment arrived. Triple therapy—a combination of three drugs called elexacaftor, tezacaftor, and ivacaftor—was designed to address the underlying genetic problem rather than just manage its symptoms. It worked well enough that it was approved for children ages 6 and older in 2022, then expanded to children as young as 2 in 2023. But researchers had noticed something curious in the clinical data: children seemed to respond even better than adolescents and adults. The question was why, and by how much.
Dr. Simon Gräber and his team at Charité – Universitätsmedizin Berlin set out to measure it directly. They enrolled 26 children between ages 2 and 11, all carrying at least one copy of the F508del mutation, one of the most common disease-causing genetic variants. Before treatment and again after four months, the researchers measured lung function, ran sweat tests—the standard diagnostic tool for cystic fibrosis, which detects salt concentration in sweat—and took small, painless samples of intestinal tissue. In the lab, they cultured those samples and measured electrical current flowing through the CFTR channels. A functioning channel transports negatively charged chloride ions; the current tells you how well it's working.
The results were striking. In adolescents and adults, triple therapy had been shown to restore CFTR channel function to about 50%. In these young children, it restored function to 90 to 100 percent—nearly indistinguishable from children without cystic fibrosis at all. "We really hadn't expected that," said Prof. Marcus Mall, director of the department where the work was conducted. "Such positive findings regarding the functional efficacy of triple therapy in children are truly remarkable and offer hope."
When the researchers compared their data with results from a previous study using the same methodology in older patients, the pattern was unmistakable: the younger the child, the more complete the restoration. There was a clear correlation with age. A 3-year-old benefited more than a 10-year-old, who benefited more than a teenager. The mechanism behind this difference remains to be understood, but the implication is profound. If early treatment can prevent the irreversible lung damage and tissue scarring that accumulates over years, starting children on triple therapy as soon as possible—potentially even before age 2—could change the trajectory of the disease entirely.
The Charité team plans to investigate further, using single-cell analysis to understand how triple therapy works at the molecular level. They are also preparing to study even younger children if the drug receives approval for that age group. For families living with cystic fibrosis, the finding suggests that the window of opportunity to prevent the worst of the disease may be wider and more powerful than anyone had realized—and that waiting, in this case, may mean losing ground that could have been held.
Notable Quotes
We really hadn't expected that the children treated with the triple therapy would have values close to normal—that is, values similar to those of children without cystic fibrosis.— Prof. Marcus Mall, director of the Department of Pediatric Respiratory Medicine at Charité
The younger the person, the more effective it is.— Dr. Simon Gräber, head of the Junior Research Group on Precision Medicine in Cystic Fibrosis
Want the full story?
Read the original at Medical Xpress ↗